Brian M. Andresen
25Patents
7h-index
105Co-inventors
72Inventor score
Filing activity: Apr 9, 1999 → Jun 18, 2020
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8551984B2 | Aminopyrimidines as SYK inhibitors | Chemistry; Metallurgy | 22 | Active |
| US8796310B2 | Amino-pyridine-containing spleen tyrosine kinase (SYK) inhibitors | Chemistry; Metallurgy | 15 | Active |
| US9487490B2 | 3-cyclohexenyl and cyclohexyl substituted indole and indazole compounds as RORgammaT inhibitors and uses thereof | Emerging Cross-Sectional Technologies | 15 | Active |
| US9663502B2 | 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease | Chemistry; Metallurgy | 12 | Active |
| US9783511B2 | Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease | Emerging Cross-Sectional Technologies | 9 | Active |
| US9809561B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | Emerging Cross-Sectional Technologies | 8 | Active |
| US10766919B2 | Cyclic di-nucleotide compounds as sting agonists | Human Necessities | 7 | Active |
| US10221146B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | Emerging Cross-Sectional Technologies | 6 | Active |
| US10738074B2 | Cyclic di-nucleotide compounds as STING agonists | Human Necessities | 5 | Active |
| US10759825B2 | Cyclic di-nucleotide compounds as STING agonists | Human Necessities | 5 | Active |
| US10513525B2 | Methods and compositions for studying, imaging, and treating pain | Chemistry; Metallurgy | 4 | Active |
| US9943516B2 | Inhibitors of IRAK4 activity | Chemistry; Metallurgy | 4 | Active |
| US9174999B2 | Methods and compositions for studying, imaging, and treating pain | Chemistry; Metallurgy | 4 | Active |
| US9969749B2 | Inhibitors of IRAK4 activity | Chemistry; Metallurgy | 4 | Active |
| US6114568A | Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors | Emerging Cross-Sectional Technologies | 2 | Expired |
| US11453697B1 | Cyclic di-nucleotide compounds as sting agonists | Human Necessities | 1 | Active |
| US10246457B2 | Indazole and azaindazole Btk inhibitors | Chemistry; Metallurgy | 1 | Active |
| US11685761B2 | Cyclic di-nucleotide compounds as sting agonists | Chemistry; Metallurgy | 0 | Active |
| US6624313B2 | Process for preparing hydroxypyrrolidinyl ethylamine compounds useful as kappa agonists | Chemistry; Metallurgy | 0 | Expired |
| US10208047B2 | Tertiary alcohol imidazopyrazine BTK inhibitors | Human Necessities | 0 | Active |
| US9085536B2 | Aconitine compounds, compositions, uses, and preparation thereof | Human Necessities | 0 | Active |
| US9598405B2 | Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors | Human Necessities | 0 | Active |
| US10745364B2 | Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease | Emerging Cross-Sectional Technologies | 0 | Active |
| US9745295B2 | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors | Chemistry; Metallurgy | 0 | Active |
| US9822107B2 | Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.